04 / ENESTop 144-Week Update: Long-Term Treatment-Free Remission (TFR) in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib

2018 ◽  
Author(s):  
Hughes Timothy P.
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Chronic Phase ◽  
Term Treatment ◽  
Second Line ◽  
Long Term Treatment ◽  
Treatment Free Remission

Long-term treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib: ENESTop 144-wk results.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 7003-7003 ◽  
Author(s):  
François-Xavier Mahon ◽  
Carla Boquimpani ◽  
Naoto Takahashi ◽  
Noam Benyamini ◽  
Nelma Cristina D. Clementino ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Chronic Phase ◽  
Term Treatment ◽  
Second Line ◽  
Long Term Treatment ◽  
Treatment Free Remission

Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update

Leukemia ◽  
2021 ◽  
Author(s):  
Timothy P. Hughes ◽  
Nelma Cristina D. Clementino ◽  
Mikhail Fominykh ◽  
Jeffrey H. Lipton ◽  
Anna G. Turkina ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Term Treatment ◽  
Second Line ◽  
Long Term Treatment ◽  
Treatment Free Remission

Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells

Leukemia ◽  
2018 ◽  
Vol 32 (12) ◽  
pp. 2572-2579 ◽  
Author(s):  
David M. Ross ◽  
◽  
Ilaria S. Pagani ◽  
Naranie Shanmuganathan ◽  
Chung H. Kok ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Term Treatment ◽  
Leukemic Cells ◽  
Long Term Treatment ◽  
Treatment Free Remission

scholarly journals Shedding Light on Targeting Chronic Myeloid Leukemia Stem Cells

2021 ◽  
Vol 10 (24) ◽  
pp. 5805
Author(s):  
Mohammad Houshmand ◽  
Alireza Kazemi ◽  
Ali Anjam Najmedini ◽  
Muhammad Shahzad Ali ◽  
Valentina Gaidano ◽  
...  
Keyword(s):  
Stem Cells ◽  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Kinase Inhibitors ◽  
Term Treatment ◽  
Leukemia Stem Cells ◽  
Hematopoietic Stem ◽  
Long Term Treatment ◽  
Treatment Free Remission

Chronic myeloid leukemia stem cells (CML LSCs) are a rare and quiescent population that are resistant to tyrosine kinase inhibitors (TKI). When TKI therapy is discontinued in CML patients in deep, sustained and apparently stable molecular remission, these cells in approximately half of the cases restart to grow, resuming the leukemic process. The elimination of these TKI resistant leukemic stem cells is therefore an essential step in increasing the percentage of those patients who can reach a successful long-term treatment free remission (TFR). The understanding of the biology of the LSCs and the identification of the differences, phenotypic and/or metabolic, that could eventually allow them to be distinguished from the normal hematopoietic stem cells (HSCs) are therefore important steps in designing strategies to target LSCs in a rather selective way, sparing the normal counterparts.

scholarly journals Evaluation of anemia after long-term treatment with imatinib in chronic myeloid leukemia patients in chronic phase

2019 ◽  
Vol 41 (4) ◽  
pp. 329-334 ◽  
Author(s):  
Muriel Silva Moura ◽  
Thais Celi Lopes Benevides ◽  
Marcia Torresan Delamain ◽  
Gislaine Oliveira Duarte ◽  
Priscila Oliveira Percout ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Chronic Phase ◽  
Term Treatment ◽  
Long Term Treatment
Sign in / Sign up

Export Citation Format

Share Document